Avita Medical’s ReCell Spray-On Skin Outperforms Traditional Skin Grafting in Clinical Study

Avita Medical, Ltd. has announced the results of a pilot study of its ReCell kit for the harvesting and application of autologous skin cells. The ReCell kit was used to treat four burn victims, and resulted in a faster healing process and better cosmetic outcomes than traditional skin grafting. Treatment with ReCell, which takes about half an hour, involves harvesting a small skin sample from the patient, using it to create a cell suspension, and spraying it over the affected area. The kit is CE marked and is currently under review by the FDA.
From the announcement:

ReCell allows in-theatre preparation of a spray-on suspension consisting of cells derived from a small (2 by 2cm), thin (0.15-0.20mm) biopsy of the patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy. The ReCell suspension contains basal keratinocytes, melanocytes, fibroblasts and Langerhans cells. The metabolically responsive epithelial cells migrate across the wound surface, leading to regeneration of skin of normal color and texture. ReCell requires only a minimal donor site and is immediate available as a cell-based spray at the patient’s bedside.

Press release: Study Demonstrates That Avita Medical’s ReCell® Spray-On Skin™ in Combination with a Biological Wound Dressing Has “a Number of Benefits Compared to Standard Skin-Grafting Techniques”…
Product page: ReCell…
Flashback: DOD Helping to Get Skin Harvesting Kit to Market